Research output per year
Research output per year
Fingerprint
Dive into the research topics where Iris Dirven is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Research output
-
1667P Psychological issues and neurocognitive functioning in long-term advanced cancer survivors treated with immune checkpoint blockade
Vanlaer, N., Dirven, I., Vounckx, M., Kessels, J., Neyns, B. & Rogiers, A., 15 Sep 2024.Research output: Unpublished contribution to conference › Poster
-
1667P Psychological issues and neurocognitive functioning in long-term advanced cancer survivors treated with immune checkpoint blockade
Vanlaer, N., Dirven, I., Vounckx, M., Kessels, J., Neyns, B. & Rogiers, A., Sep 2024, In: Annals of Oncology. 35, 1 p., S1004.Research output: Contribution to journal › Meeting abstract (Journal)
Open Access -
A randomized phase II clinical trial of stereotactic body radiation therapy (SBRT) and systemic pembrolizumab with or without intratumoral avelumab/ipilimumab plus CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells in solid tumors
Vounckx, M., Tijtgat, J., Stevens, L., Dirven, I., Ilsen, B., Vandenbroucke, F., Raeymaeckers, S., Vekens, K., Forsyth, R., Geeraerts, X., Van Riet, I., Schwarze, J. K., Tuyaerts, S., Decoster, L., De Ridder, M., Dufait, I. & Neyns, B., 2 Jul 2024, In: Cancer Immunol Immunother. 73, 9, 8 p., 167.Research output: Contribution to journal › Article › peer-review
Open AccessFile -
Emotional Distress, Cognitive Complaints, and Care Needs among Advanced Cancer Survivors Treated with Immune Checkpoint Blockade: A Mixed-Method Study
Vanlaer, N., Dirven, I., Neyns, B. & Rogiers, A., 24 Apr 2024, In: Cancers. 16, 9, 17 p., 1638.Research output: Contribution to journal › Article › peer-review
Open AccessFile -
Intracranial administration of anti-PD-1 and anti-CTLA-4 immune checkpoint-blocking monoclonal antibodies in patients with recurrent high-grade glioma
Duerinck, J., Lescrauwaet, L., Dirven, I., Del'haye, J., Stevens, L., Geeraerts, X., Vaeyens, F., Geens, W., Brock, S., Vanbinst, A-M., Everaert, H., Caljon, B., Bruneau, M., Lebrun, L., Salmon, I., Kockx, M., Tuyaerts, S. & Neyns, B., 2024, In: Neuro-oncology. 14 p., noae177.Research output: Contribution to journal › Article › peer-review
Prizes
Activities
-
Melanoma treatment Anno 2024
Iris Dirven (Speaker)
9 Mar 2024Activity: Talk or presentation › Talk at a public lecture/debate
-
Investigating the clinical application and in vitro effect of regorafenib in advanced and metastatic melanoma and overcoming acquired resistance to targeted therapies.
Iris Dirven (Presenter)
27 Feb 2023Activity: Other › Written proposal
File -
Splenic angiosarcoma with hepatic metastases: A rare cause of hepatic failure
Iris Dirven (Speaker), Laura Emma J Braeckeveldt (Contributor), Hendrik Reynaert (Contributor), Pierre Lefesvre (Contributor), Vandenbroucke Frederik (Contributor) & Magali Marie Surmont (Contributor)
9 Mar 2023Activity: Talk or presentation › Talk or presentation at a conference
-
Analysis of cell-free tumor DNA in cerebrospinal fluid as a diagnostic biomarker for leptomeningeal melanoma metastasis: a case series
Iris Dirven (Speaker)
21 Apr 2023Activity: Talk or presentation › Talk or presentation at a conference
-
Donateursontmoeting Kom Op Tegen Kanker
Manon Vounckx (Speaker) & Iris Dirven (Speaker)
13 Oct 2023Activity: Talk or presentation › Talk at a public lecture/debate